Loading stock data…
PRAX
$250.33-2.92 (-1.15%)
Market ClosedLast close Jun 9
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $250.33. Wall Street consensus targets $627.59 (17 analysts), implying a +150.7% move over the next 12 months. The stock is currently 32% below its 52-week high of $366.52, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +150.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$250.33
Potential Downside
0%
Whystock Fair Value$250.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$627.59+150.7%
Range$162.00 – $1201
Fundamentals
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.16%
Volume
Today's trading volume
426,392
Recent News
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study. This research evaluated the effectiveness of vormatrigine as a treatment for individuals with focal onset seizures. This study […]
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy Pipeline
Praxis Precision Medicines paused enrollment in its POWER2 study after vormatrigine did not meet the primary endpoint in the POWER1 trial for focal onset seizures. The company plans to reassess the vormatrigine program following the POWER1 outcome. For investors watching NasdaqGS:PRAX, this setback affects a key part of the epilepsy pipeline at a time when the stock has already seen sharp moves. Shares recently closed at $258.08, with the stock down 26.4% over the past week and 20.4% over...
Stock Indexes Post New Record Highs Amid AI Enthusiasm
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.13%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.45%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.48%. June E-mini S&P futures (ESM26 ) rose +0.14%, and June E-mini Nasdaq futures...
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive
Praxis Precision Medicines unexpectedly halted enrollment in a late-stage study of its seizure drug. Praxis stock tumbled.